Palatin Tech puts end to Vyleesi license agreement with Amag Pharma
Seeking Alpha · 07/27 12:39
Palatin Technologies Terminates its Agreement Granting AMAG Pharma Exclusive North American Reights to Market Vyleesi
Benzinga · 07/27 11:03
5 Health Care Stocks Trading With Low Price-Earnings Ratios
Genesis tops the list Continue reading...
GuruFocus.com · 07/14 17:19
Moderna's COVID-19 Vaccine And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/12 08:52
Palatin resumes enrollment in mid-stage dry eye study
Seeking Alpha - Article · 07/08 13:20
Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease
PR Newswire · 07/08 12:30
Palatin Technologies, Inc. Announces Reinitiation Of Enrollment Of Phase 2 Study With PL9643 For Treatment Of Dry Eye Disease
CRANBURY, N.J., July 8, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the
Benzinga · 07/08 11:33
Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.